JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AstraZeneca PLC ADR

Uždarymo kaina

73.59 -1.31

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

73.52

Max

73.74

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-923M

2.5B

Pardavimai

1B

15B

P/E

Sektoriaus vid.

27.832

34.393

Dividendų pajamingumas

2.12

Pelno marža

16.947

Darbuotojai

94,300

EBITDA

-18M

5B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+26.44% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.12%

2.54%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.1B

231B

Ankstesnė atidarymo kaina

74.9

Ankstesnė uždarymo kaina

73.59

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

AstraZeneca PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-29 08:08; UTC

Uždarbis

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

2025-07-29 06:46; UTC

Uždarbis

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

2025-08-08 10:51; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

2025-08-01 11:10; UTC

Karštos akcijos

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

2025-07-29 11:02; UTC

Uždarbis

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

2025-07-29 11:02; UTC

Uždarbis

AstraZeneca 2Q EPS $1.58 >AZN.LN

2025-07-29 11:01; UTC

Uždarbis

AstraZeneca 2Q Rev $14.5B >AZN.LN

2025-07-29 11:00; UTC

Uždarbis

AstraZeneca Results: H1 and Q2 2025

2025-07-29 08:00; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

2025-07-29 07:53; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

2025-07-29 07:26; UTC

Rinkos pokalbiai
Uždarbis

AstraZeneca Shares Look Undervalued -- Market Talk

2025-07-29 06:03; UTC

Uždarbis

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

2025-07-29 06:03; UTC

Uždarbis

AstraZeneca 2Q Total Revenue $14.46B

2025-07-29 06:03; UTC

Uždarbis

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

2025-07-29 06:03; UTC

Uždarbis

AstraZeneca 2Q Core EPS $2.17

2025-07-29 06:02; UTC

Uždarbis

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

2025-07-29 06:02; UTC

Uždarbis

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

2025-07-29 06:02; UTC

Uždarbis

AstraZeneca Backs 2025 View

2025-07-29 06:00; UTC

Uždarbis

AstraZeneca PLC 2Q Rev $14.46B

2025-07-29 06:00; UTC

Uždarbis

AstraZeneca PLC 2Q Adj EPS $2.17

2025-07-29 06:00; UTC

Uždarbis

AstraZeneca PLC 2Q Pretax Pft $3.13B

2025-07-29 06:00; UTC

Uždarbis

AstraZeneca PLC 2Q Net Pft $2.45B

2025-07-29 06:00; UTC

Uždarbis

AstraZeneca PLC 2Q Oper Pft $3.51B

2025-07-29 06:00; UTC

Uždarbis

AstraZeneca PLC 2Q EPS $1.57

2025-07-28 10:51; UTC

Rinkos pokalbiai

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

2025-07-22 10:19; UTC

Rinkos pokalbiai

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

2025-07-22 09:34; UTC

Karštos akcijos

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

2025-07-09 10:59; UTC

Rinkos pokalbiai

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

2025-07-09 09:17; UTC

Karštos akcijos

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

2025-05-28 18:09; UTC

Uždarbis

Heart Disease Could Be a Goner When These New -2-

Akcijų palyginimas

Kainos pokytis

AstraZeneca PLC ADR Prognozė

Kainos tikslas

By TipRanks

26.44% į viršų

12 mėnesių prognozė

Vidutinis 93 USD  26.44%

Aukščiausias 97 USD

Žemiausias 85 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AstraZeneca PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 69.55Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.